MedicationsComments Off on First Patient Enrolled In Biohaven’s Phase 2/3 Mild-to-Moderate Alzheimer’s Clinical Trial
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok